Welcome to LookChem.com Sign In|Join Free

CAS

  • or

866566-04-3

Post Buying Request

866566-04-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

866566-04-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 866566-04-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,5,6 and 6 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 866566-04:
(8*8)+(7*6)+(6*6)+(5*5)+(4*6)+(3*6)+(2*0)+(1*4)=213
213 % 10 = 3
So 866566-04-3 is a valid CAS Registry Number.

866566-04-3Downstream Products

866566-04-3Relevant articles and documents

Fluorinated Cycloplatinated(II) Complexes Bearing Bisphosphine Ligands as Potent Anticancer Agents

Shahsavari, Hamid R.,Hu, Jiyun,Chamyani, Samira,Sakamaki, Yoshie,Aghakhanpour, Reza Babadi,Salmon, Christopher,Fereidoonnezhad, Masood,Mojaddami, Ayyub,Peyvasteh, Parnian,Beyzavi, Hudson

, p. 72 - 82 (2021/01/09)

A family of cationic cycloplatinated(II) complexes [Pt(dfppy)(P^P)]Cl incorporating bisphosphine ligands was prepared: (dfppy = 2-(2,4-difluorophenyl)pyridine; P^P = bis(diphenylphosphino)methane (1, dppm), 1,2-bis(diphenylphosphino)ethane (2, dppe), 1,2-bis(diphenylphosphino)benzene (3, dppbz)). The complexes were characterized by means of several analytical and spectroscopic methods. These complexes displayed acceptable stability in biological environments, which was confirmed by NMR, HR ESI-MS, and UV-vis techniques. The antiproliferative properties of these complexes were evaluated by the National Cancer Institute (NCI) against 60 different human tumor cell lines such as leukemia, melanoma, lung, colon, brain, ovary, breast, prostate, and kidney. These complexes showed higher cytotoxicity in comparison to cisplatin against a wide variety of cancer cell lines such as K-562 (leukemia), HOP-92 (lung), HCT-116 (colon), OVCAR-8 (ovarian), PC-3 (prostate), MDA-MB-468 (breast), and melanoma cancer cell lines. Complex 3, as the most potent compound in this study, furnished an excellent antiproliferative activity in comparison to cisplatin against Hela, SKOV3, and MCF-7 cancer cell lines. The main mode of the interactions of 1-3 with DNA was also determined using molecular docking studies.

Anionic cyclometalated Pt(ii) and Pt(iv) complexes respectively bearing one or two 1,2-benzenedithiolate ligands

Ionescu, Andreea,Godbert, Nicolas,Aiello, Iolinda,Ricciardi, Loredana,La Deda, Massimo,Crispini, Alessandra,Sicilia, Emilia,Ghedini, Mauro

, p. 11645 - 11657 (2018/08/28)

Novel anionic cyclometalated Pt(ii) square-planar complexes NBu4[(C^N)PtII(S^S)], containing 2-phenylpyridine H(PhPy), 2-(2,4-difluorophenyl)-pyridine H(F2PhPy) and benzo[h]quinoline H(Bzq), respectively, as a cyclometalated ligand and the dianionic 1,2-benzenedithiolate (Thio)2- fragment as an (S^S) ligand, were synthesised. By the simple addition of an equivalent of (Thio)2- to the NBu4[(C^N)PtII(Thio)] complexes, octahedral anionic NBu4[(C^N)PtIV(Thio)2] analogues were obtained, representing, to the best of our knowledge, the first examples of Pt(iv) anionic cyclometalated complexes. The molecular structures of the obtained complexes in the case of the NBu4[(Bzq)PtII(Thio)] and the NBu4[(Bzq)PtIV(Thio)2] complexes were confirmed by single crystal X-ray diffraction analysis. Furthermore, the electrochemical and photophysical properties of the two series of Pt(ii) and Pt(iv) newly synthesised complexes were studied and DFT and TD-DFT calculations were performed in order to comprehensively investigate the displayed behaviour. All Pt(ii) and Pt(iv) complexes show intense luminescence in the solid state, with remarkable enhancement of the emission quantum yields, proving to be excellent examples of aggregation-induced emission systems.

Anionic cyclometallated Pt(II) square-planar complexes: New sets of highly luminescent compounds

Ricciardi, Loredana,La Deda, Massimo,Ionescu, Andreea,Godbert, Nicolas,Aiello, Iolinda,Ghedini, Mauro

, p. 12625 - 12635 (2017/10/06)

Two series of novel NBu4+ salts of anionic cyclometallated Pt(ii) complexes were synthesized and fully characterized. These highly luminescent compounds (NBu4[(C^N)Pt(O^N)] and NBu4[(C^N)Pt(O^O)]) are incorporated as testing examples of cyclometallating ligands 2-phenylpyridine (PhPy), 2-(2,4-difluorophenyl)-pyridine (F2PhPy) and 2-thienylpyridine (ThPy), and a benzo[h]quinoline (Bzq) fragment. All complexes display a square-planar coordination sphere, wherein the (C^N)Pt fragment is completed either by an O^N orotate (Ort) or an O^O tetrabromocatecholate (Cat) ligand. The HOMO and LUMO levels of all complexes were estimated by cyclic voltammetry and a comprehensive electrochemical and photophysical study was performed. The new complexes are emissive in solution at 298 K and the NBu4[(ThPy)Pt(Ort)] complex displays good photosensitizing properties (Φ = 28% in deaerated solution vs. Φ = 1.4% in the presence of O2). Both series of NBu4[(C^N)Pt(Ort)] and NBu4[(C^N)Pt(Cat)] complexes are highly luminescent in the solid state (emission quantum yields from 10 to 85%). Remarkably, the square-planar Pt(ii) anionic complexes showed an important increase in luminescence quantum yields on changing from the dilute solution to the solid state (the most significant from 0.13% to 85% for the NBu4[(PhPy)Pt(Ort)] complex, an ideal candidate as an active species for LEECs).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 866566-04-3